Partner Laura Ganoza’s appointment as chair of Foley’s Miami litigation practice was featured in a Daily Business Review article, “Laura Ganoza Leads Foley & Lardner’s Miami Litigation Team.”
As practice chair, Ganoza will oversee litigation with a principal focus on associate and senior counsel development, including training and mentoring.
Ganoza handles complex commercial and intellectual property litigation, including cross-border disputes, trade secret and noncompete actions, and manages trademark and copyright portfolios. She is also the regional director of the South Florida chapter of Fashion Group International, a 5,000-member global fashion industry nonprofit.
As practice chair, Ganoza will oversee litigation with a principal focus on associate and senior counsel development, including training and mentoring.
Ganoza handles complex commercial and intellectual property litigation, including cross-border disputes, trade secret and noncompete actions, and manages trademark and copyright portfolios. She is also the regional director of the South Florida chapter of Fashion Group International, a 5,000-member global fashion industry nonprofit.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”